Alaunos Therapeutics, Inc. (TCRT)
TCRT Stock Price Chart
Explore Alaunos Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TCRT price movements and trends.
TCRT Company Profile
Discover essential business fundamentals and corporate details for Alaunos Therapeutics, Inc. (TCRT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Aug 2005
Employees
1.00
Website
https://www.alaunos.comCEO
Dale Curtis Hogue Jr.
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
TCRT Financial Timeline
Browse a chronological timeline of Alaunos Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$0.63 surpassing the estimated -$5.33 by +88.19%.
Earnings released on 15 May 2025
EPS came in at -$0.67 surpassing the estimated -$6.44 by +89.60%, while revenue for the quarter reached $2.00K .
Earnings released on 31 Mar 2025
EPS came in at -$0.46 surpassing the estimated -$4.50 by +89.78%, while revenue for the quarter reached $4.00K .
Earnings released on 14 Nov 2024
EPS came in at -$0.70 surpassing the estimated -$4.50 by +84.44%.
Earnings released on 14 Aug 2024
EPS came in at -$0.71 surpassing the estimated -$4.50 by +84.22%, while revenue for the quarter reached $4.00K .
Stock split effective on 18 Jul 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2024
EPS came in at -$1.10 surpassing the estimated -$4.50 by +75.56%, while revenue for the quarter reached $1.00K .
Earnings released on 2 Apr 2024
EPS came in at -$0.49 falling short of the estimated -$0.45 by -8.89%, while revenue for the quarter reached $1.00K .
Stock split effective on 1 Feb 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$6.00 falling short of the estimated -$4.50 by -33.33%.
Earnings released on 14 Aug 2023
EPS came in at -$6.00 matching the estimated -$6.00, while revenue for the quarter reached $4.00K .
Earnings released on 10 May 2023
EPS came in at -$6.00 matching the estimated -$6.00.
Earnings released on 7 Mar 2023
EPS came in at -$6.00 surpassing the estimated -$13.49 by +55.52%, while revenue for the quarter reached $11.00K .
Earnings released on 14 Nov 2022
EPS came in at -$6.00 surpassing the estimated -$17.99 by +66.65%, while revenue for the quarter reached $2.91M .
Earnings released on 15 Aug 2022
EPS came in at -$7.50 surpassing the estimated -$16.49 by +54.52%.
Earnings released on 16 May 2022
EPS came in at -$7.50 surpassing the estimated -$13.49 by +44.40%.
Earnings released on 30 Mar 2022
EPS came in at -$7.50 surpassing the estimated -$13.49 by +44.40%.
Earnings released on 8 Nov 2021
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $398.00K .
Earnings released on 13 Aug 2021
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 6 May 2021
EPS came in at -$0.10 matching the estimated -$0.10.
Earnings released on 25 Feb 2021
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%.
Earnings released on 5 Nov 2020
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%.
TCRT Stock Performance
Access detailed TCRT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.